Optegra
27 November 2020
The ophthalmology group, Optegra, has been acquired by investment firm H2 Equity Partners in what the company has called “the start of an exciting next chapter.”
The acquisition is expected to be completed in early 2021, following the satisfaction of certain regulatory conditions.
Under the new investment, Optegra’s management team will work closely with H2, the company said in a statement, to deliver an “ambitious growth strategy” as well as ensuring the business “continues to provide excellent care and service to its patients.”
Commenting on the acquisition, CEO Dr Peter Byloos told OT: "This investment is the start of an exciting next chapter for Optegra and we look forward to working in partnership with H2 to further grow the business and explore new opportunities.”
The ophthalmology group has 23 eye hospitals across the United Kingdom, the Czech Republic and Poland. The group provides a range of eye care services including cataract surgeries, age-related macular degeneration treatment and vision correction procedures.
The business also provides services to publicly-funded national healthcare systems such as the NHS, and to private patients.
Dr Byloos said Optegra had seen an “incredibly successful year, even in the face of all the challenges of 2020,” telling OT: “We have aligned our organisation towards our critical pathways and as a team everyone has worked so hard, enabling us to deliver fantastic results.”
He added: "We are proud to be supporting the NHS, enabling them to reduce the number of patients awaiting urgent cataract and AMD treatments, as well as continuing to grow our successful vision correction offering for private patients with our latest technology.”
The agreement with Optegra represents the ninth investment for H2 Equity Partners Fund V, an arm of the firm which makes investments in the United Kingdom, Ireland and Benelux.
Patrick Kalverboer, managing partner for H2, shared that the firm looks forward to supporting Optegra in “reaching its full potential in the next phase of its development.”
The acquisition is expected to be completed in early 2021, following the satisfaction of certain regulatory conditions.
Under the new investment, Optegra’s management team will work closely with H2, the company said in a statement, to deliver an “ambitious growth strategy” as well as ensuring the business “continues to provide excellent care and service to its patients.”
Commenting on the acquisition, CEO Dr Peter Byloos told OT: "This investment is the start of an exciting next chapter for Optegra and we look forward to working in partnership with H2 to further grow the business and explore new opportunities.”
The ophthalmology group has 23 eye hospitals across the United Kingdom, the Czech Republic and Poland. The group provides a range of eye care services including cataract surgeries, age-related macular degeneration treatment and vision correction procedures.
The business also provides services to publicly-funded national healthcare systems such as the NHS, and to private patients.
Dr Byloos said Optegra had seen an “incredibly successful year, even in the face of all the challenges of 2020,” telling OT: “We have aligned our organisation towards our critical pathways and as a team everyone has worked so hard, enabling us to deliver fantastic results.”
He added: "We are proud to be supporting the NHS, enabling them to reduce the number of patients awaiting urgent cataract and AMD treatments, as well as continuing to grow our successful vision correction offering for private patients with our latest technology.”
The agreement with Optegra represents the ninth investment for H2 Equity Partners Fund V, an arm of the firm which makes investments in the United Kingdom, Ireland and Benelux.
Patrick Kalverboer, managing partner for H2, shared that the firm looks forward to supporting Optegra in “reaching its full potential in the next phase of its development.”
Comments (0)
You must be logged in to join the discussion. Log in